We are live on ! Find out more
SRRA

Sierra Oncology, Inc. Common Stock
SRRA

Delisted

SRRA was delisted on the 30th of June, 2022.

Back to rankings

44 hedge funds and large institutions have $48M invested in Sierra Oncology, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

232% more capital invested

Capital invested by funds: $14.4M → $48M (+$33.6M)

129% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 7

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

22% more funds holding

Funds holding: 36 → 44 (+8)

Holders
44
Holders Change
+8
Holders Change %
+22.22%
% of All Funds
1.1%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
16
Increased
9
Reduced
7
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FM
Frazier Management
Washington
+$8.61M
2
DM
Deerfield Management
New York
+$5.53M
3
O
OrbiMed
New York
+$5.38M
4
PA
Perceptive Advisors
New York
+$5.38M
5
NLVP
New Leaf Venture Partners
New York
+$3.77M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$298K
2
BCM
Bridgeway Capital Management
Texas
-$212K
3
Goldman Sachs
Goldman Sachs
New York
-$59K
4
JP Morgan Chase
JP Morgan Chase
New York
-$39.9K
5
VKH
Virtu KCG Holdings
New York
-$38.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
FM
1
Frazier Management
Washington
$12.4M +$8.61M +148,148 +271%
DM
2
Deerfield Management
New York
$7.61M +$5.53M +95,143 +326%
O
3
OrbiMed
New York
$5.67M +$5.38M +92,593 New
PA
4
Perceptive Advisors
New York
$5.67M +$5.38M +92,593 New
NLVP
5
New Leaf Venture Partners
New York
$3.97M +$3.77M +64,815 New
VC
6
Vivo Capital
California
$3.73M – – –
SM
7
Sabby Management
Florida
$2.67M +$1.17M +20,136 +86%
PNC Financial Services Group
8
PNC Financial Services Group
Pennsylvania
$1.14M – – –
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$837K +$769K +13,233 +2,994%
AIC
10
AWM Investment Company
New York
$765K – – –
NC
11
Nexthera Capital
New York
$612K +$581K +10,000 New
DCM
12
DAFNA Capital Management
California
$405K +$385K +6,625 New
GT
13
Greenleaf Trust
Michigan
$328K – – –
SAM
14
Sectoral Asset Management
Quebec, Canada
$309K +$293K +5,042 New
Fidelity Investments
15
Fidelity Investments
Massachusetts
$302K – – –
PAM
16
Panagora Asset Management
Massachusetts
$250K +$116K +1,995 +96%
BCM
17
Bridgeway Capital Management
Texas
$205K -$212K -3,650 -52%
VMI
18
VHCP Management II
New York
$200K – – –
Millennium Management
19
Millennium Management
New York
$172K +$92.3K +1,588 +130%
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$130K -$6.86K -118 -5%
William Blair & Company
21
William Blair & Company
Illinois
$70K – – –
Geode Capital Management
22
Geode Capital Management
Massachusetts
$59K +$36.8K +633 +187%
MA
23
Minerva Advisors
Pennsylvania
$58K -$21.9K -376 -32%
SKK
24
Shepherd Kaplan Krochuk
Massachusetts
$58K +$55.2K +950 New
WS
25
Wedbush Securities
California
$54K +$8.95K +154 +21%
1
2

SRRA Hedge Fund Activity: Q1 2017 in Review

44 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q1 2017, worth a combined $48M — up 232% from $14.4M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new SRRA positions and 7 closed out — a net gain of 9 holders — while 9 added to existing stakes and 7 trimmed.

The largest buyer was Frazier Management, adding an estimated $8.61M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $298K sold.

  • 44 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q1 2017, up from 36 in Q4 2016.
  • Funds reported $48M of Sierra Oncology, Inc. Common Stock stock for Q1 2017, up 232% quarter-over-quarter.
  • 16 funds opened new Sierra Oncology, Inc. Common Stock positions in Q1 2017 and 7 closed out, a net change of +9 holders.
  • The largest Sierra Oncology, Inc. Common Stock buyer in Q1 2017 was Frazier Management, an estimated $8.61M added.
  • The largest Sierra Oncology, Inc. Common Stock seller in Q1 2017 was Baker Bros. Advisors, an estimated $298K sold.

Based on aggregated 13F filings for Q1 2017.